Tuning immune tolerance with vasoactive intestinal peptide: A new therapeutic approach for immune disorders

被引:33
作者
Pozo, David
Gonzalez-Rey, Elena
Chorny, Alejo
Anderson, Per
Varela, Nieves
Delgado, Mario
机构
[1] CSIC, Inst Parasitol & Biomed, E-18100 Granada, Spain
[2] Univ Seville, Dept Bioquim Med & Biol Mol, E-41009 Seville, Spain
关键词
inflammation; autoimmunity; regulatory T cells; tolerance; neuroimmunology; neuropeptide;
D O I
10.1016/j.peptides.2007.04.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The induction of immune tolerance is essential for the maintenance of immune homeostasis and to limit the occurrence of exacerbated inflammatory and autoimmune conditions. Multiple mechanisms act together to ensure self-tolerance, including central clonal deletion, cytokine deviation and induction of regulatory T cells. Identifying the factors that regulate these processes is crucial for the development of new therapies of autoimmune diseases and transplantation. The vasoactive intestinal peptide (VIP) is a well-characterized endogenous anti-inflammatory neuropeptide with therapeutic potential for a variety of immune disorders. Here, we examine the latest research findings, which indicate that VIP participates in maintaining immune tolerance in two distinct ways: by regulating the balance between pro-inflammatory and anti-inflammatory factors, and by inducing the emergence of regulatory T cells with suppressive activity against autoreactive T-cell effectors. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1833 / 1846
页数:14
相关论文
共 99 条
[1]   Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease [J].
Abad, C ;
Martinez, C ;
Juarranz, MG ;
Arranz, A ;
Leceta, J ;
Delgado, M ;
Gomariz, RP .
GASTROENTEROLOGY, 2003, 124 (04) :961-971
[2]   VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease [J].
Bangale, Y ;
Karle, S ;
Planque, S ;
Zhou, YX ;
Taguchi, H ;
Nishiyama, Y ;
Li, L ;
Kalaga, R ;
Paul, S .
FASEB JOURNAL, 2003, 17 (06) :628-635
[3]   PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease [J].
Banner, KH ;
Trevethick, MA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (08) :430-436
[4]   The immune system as the sixth sense [J].
Blalock, JE .
JOURNAL OF INTERNAL MEDICINE, 2005, 257 (02) :126-138
[5]   Regulatory T-cell therapy: is it ready for the clinic? [J].
Bluestone, JA .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :343-349
[6]   DESIGN AND DEVELOPMENT OF A VASOACTIVE-INTESTINAL-PEPTIDE ANALOG AS A NOVEL THERAPEUTIC FOR BRONCHIAL-ASTHMA [J].
BOLIN, DR ;
MICHALEWSKY, J ;
WASSERMAN, MA ;
ODONNELL, M .
BIOPOLYMERS, 1995, 37 (02) :57-66
[7]  
Brandt N, 2000, GENERATIONS, V24, P37
[8]   Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors [J].
Castro, A ;
Jerez, MJ ;
Gil, C ;
Martinez, A .
MEDICINAL RESEARCH REVIEWS, 2005, 25 (02) :229-244
[9]   Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders [J].
Chorny, A ;
Gonzalez-Rey, E ;
Fernandez-Martin, A ;
Pozo, D ;
Ganea, D ;
Delgado, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (38) :13562-13567
[10]   Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response [J].
Chorny, A ;
Gonzalez-Rey, E ;
Fernandez-Martin, A ;
Ganea, D ;
Delgado, M .
BLOOD, 2006, 107 (09) :3787-3794